Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

JNJ-26854165 is an antagonist of MDM2 that suppresses the growth of cancer cell lines expressing wild-type p53 (IC50 values range from 240-440 nM).1 It induces p53-mediated transcription culminating in apoptotic death of acute leukemia cells.1 JNJ-26854165 is orally bioavailable and has anti-proliferative as well as apoptotic actions in various tumor models.2 As MDM2 interacts with and modulates several targets in addition to p53, JNJ-26854165 affects multiple signaling pathways.2,3,4
WARNING This product is not for human or veterinary use.
1. The novel tryptamine derivative JNJ-
2. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J. Hematol. Oncol. 4(16), 1-14 (2011).
3. Serdemetan antagonizes the Mdm2-
4. The novel anticancer agent JNJ-